Read PDF
Lund, Sweden, 25 October 2018 – Xintela announces today that the company has signed a co-development agreement with the American company Redwood Bioscience Inc., a wholly owned subsidiary of Catalent, Inc., a world leader in antibody-drug conjugate (ADC) technology for cancer therapy. The parties intend to jointly develop an ADC therapeutic product with a first focus on glioblastoma, the most common and most aggressive form of brain tumours in adults. The parties will co-finance the development and jointly work to license the project to a third party for clinical studies and commercialization.
Xintela has previously reported positive results in the company’s glioblastoma project using an ADC, based on a specific antibody which was found to target and kill glioblastoma cells in preclinical models. Xintela is now taking the next step in the development together with Catalent, to develop and evaluate ADC candidates for clinical trials. The ADCs will be a combination of Xintela’s antibodies with Catalent’s SMARTag® ADC technology which has been developed by Redwood Bioscience, Inc.
“This is an important milestone for Xintela's oncology business. Catalent's technology and extensive experience in the ADC area give Xintela the optimal conditions to effectively develop the brain cancer project towards clinical studies and commercialization. The collaboration also gives our oncology business a valuable foundation for the upcoming spin-out of the new company Targinta AB,” said Evy Lundgren Åkerlund, CEO Xintela AB.
“Xintela has an exciting oncology target technology and promising preclinical results, which is why we are eager to invest together with Xintela to co-develop a treatment for brain cancer,” said David Rabuka, Global Head of R&D, Chemical Biology, Catalent.
About Redwood Bioscience, Inc.
Catalent’s proprietary SMARTag® platform provides site-specific protein-modification and linker technologies. It was developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. Catalent acquired Redwood Bioscience Inc., in 2014.
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se
About Xintela
Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company’s oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 25th of October 2018, at 08.30 CEST.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Chairman Gregory Batcheller visited BioStock’s studio to tell us more about the company’s journey and business development.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Investor Meeting on March 16, 2023.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Fall Summit 2022 on November 30.
CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.
Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).
BioStock interview with Xintela's CMO and board member Sven Kili.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
